Medidata Launches myMedidata LIVE: Patient-Facing Video Visit Capability Built Directly into the Rave EDC Platform

  • myMedidata provides patients with virtual access to all of their study needs in a single web application
  • Developed with Medidata’s Patient Insights group to improve the overall patient experience, myMedidata provides a suite of virtualized research technologies built on the life science industry’s most used data engine – Rave EDC (electronic data capture)
  • eConsent and eCOA (clinical outcomes assessment) also added to this newest myMedidata release
logo > Dassault Systèmes

NEW YORK, October 14, 2020 -- Medidata, a Dassault Systèmes Company, the global leader in creating end-to-end solutions supporting the entire clinical trial process today announced the availability of myMedidata LIVE, a new feature on the myMedidata patient portal. myMedidata LIVE is a web-based, live video conferencing capability connecting patients virtually with their clinical trial study staff. Built on the industry’s leading Rave EDC (electronic data capture) platform already in use at more clinical research sites globally than any other system, myMedidata LIVE gives researchers and patients a way to engage in remote site visits within the platform of site and patient-facing technologies they are already using on the study. 
 
myMedidata is Medidata’s newly released patient portal solution that provides patients with virtual access to all of their study needs in a single web application. It is built using responsive design principles -- as well as input from Medidata’s Patient Insights team, a group of patients and patient advocates -- and made to be accessible from any device with an internet connection. Particularly relevant during the current COVID-19 pandemic when in-person visits might be restricted,  myMedidata LIVE video visits between patients and sites can replace scheduled site-based appointments and allow the study team to complete its data entry in Rave while the patients remain engaged offsite through myMedidata.
 
"The COVID-19 global pandemic represents a pivotal moment for virtual care as healthcare organizations seek ways to triage COVID-19 patients while minimizing exposure between patients and clinicians and continue to see patients fearful of catching COVID-19 if they visit the hospital or their physician's office," said Lynne A. Dunbrack, group vice president, IDC Health Insights.*
 
“myMedidata LIVE brings a meaningful capability to the clinical research community as virtualization technologies take on an increasingly important role,” said Anthony Costello, senior vice president of mHealth at Medidata. “As part of our myMedidata patient portal, patients and sites can rely on myMedidata LIVE as an alternative way to engage when in-person site visits are challenging or impossible.”
 
The latest version of myMedidata also includes two other important clinical tools, which have been redesigned for virtual use and can now be used through the web with a patient’s myMedidata account: myMedidata eConsent and myMedidata eCOA (clinical outcomes assessment). Both tools give sites the ability to maintain a consistent and traceable process, since they are directly integrated with Rave EDC, and use the same advanced, trusted technology previously accessed through the eConsent and eCOA apps. In addition, myMedidata eConsent now provides patients the opportunity to learn about and consent to clinical trials at home or at a remote location, and myMedidata eCOA easily and accurately captures patient outcomes.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
 
*IDC PlanScape: Virtual Care," US44610619. May 2020

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit https://www.3ds.com